Structural basis for the inhibition of βFXIIa by garadacimab
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0969-2126
-
Container-title:Structure
-
language:en
-
Short-container-title:Structure
Author:
Drulyte Ieva,
Ghai Rajesh,
Ow Saw Yen,
Kapp Eugene A.,
Quek Adam J.,
Panousis Con,
Wilson Michael J.,
Nash Andrew D.,
Pelzing MatthiasORCID
Reference25 articles.
1. C1 inhibitor, a multi-functional serine protease inhibitor;Davis;Thromb. Haemost.,2010
2. Reincarnation of ancient links between coagulation and complement;Conway;J. Thromb. Haemost.,2015
3. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor;de Agostini;J. Clin. Invest.,1984
4. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Craig;Lancet,2023